Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong anti-tumor activity in advanced non-small-cell-lung cancer patients

Cancer Biology and Therapy

Volumn 9, Issue 9, 2010, Pages 683-691

  Correale, Pierpaolo ^a   Remondo, Cinzia ^a   Carbone, Salvatore Francesco ^b   Ricci, Veronica ^b   Migali, Cristina ^a   Martellucci, Ignazio ^a   Licchetta, Antonella ^a   Addeo, Raffaele ^c   Volterrani, Luca ^b   Gotti, Giuseppe ^b   Rotundo, Maria Saveria ^d   Tassone, Pierfrancesco ^d   Sperlongano, Pasquale ^e   Abbruzzese, Alberto ^e   Caraglia, Michele ^e   Tagliaferri, Pierosandro ^d   Francini, Guido ^a  

^a Medical Oncology Section   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bevacizumab; Cisplatin; Etoposide; Metronomic therapy; NSCLC

Indexed keywords

ANGIOPOIETIN 1; BEVACIZUMAB; CISPLATIN; ETOPOSIDE; HUMAN MONOCLONAL ANTIBODY; THROMBOSPONDIN 1; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; THROMBOSPONDIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BRONCHIOLITIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEPRESSION; DRUG DOSE ESCALATION; FEMALE; HEMOPTYSIS; HUMAN; LEUKOPENIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PNEUMONIA; SCORING SYSTEM; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; ADVANCED CANCER; ALOPECIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CELL TRANSPORT; COGNITIVE DEFECT; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; KIDNEY FAILURE; LUNG CAVITATION; LUNG EMBOLISM; MUCOSA INFLAMMATION; PERFUSION; STOMATITIS; TREATMENT RESPONSE; ADENOCARCINOMA; BLOOD; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; LUNG TUMOR; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-1; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOSPONDINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953720221     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. Version 1.0. IARC CancerBase [N05 Lyon]. IARCPress; http://www-de.iarc.fr/ globocan.htlm.
2. Schrump DS, Altorki NK, Hensechle CL. Cancer of the Lung: Non-Small Cell Lung Cancer, In De Vita VTJ, Hellman S, Rosenberg SA. (eds) Cancer Principles and Practice of Oncology. Lippincott Williams and Wilkins. Philadelphia 2005; 753-77.
3. Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials. Lung Cancer 2008; 59:16-9.
4. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28:1779-802. (Pubitemid 46038527)
5. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8:579-91.
6. Midgley R, Kerr D. Bevacizumab: current status and future directions. Ann Oncol 2005; 16:999-1004. (Pubitemid 41418303)
7. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103-11.
8. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422-8.
9. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
10. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-9.
11. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008; 26:3523-9.
12. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. (Pubitemid 44917502)
13. Reck M, Von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-34.
14. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-91.
15. Scharovsky OD, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 2009; 16:7-15.
16. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423-36.
17. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106:3058-61. (Pubitemid 41565900)
18. Laquente B, Viñals F, Germà JR. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol 2007; 9:93-8.
19. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-8.
20. Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, et al. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 2006; 16:133-40.
21. Khosravi Shahi P, Fernández Pineda I. Tumoral angiogenesis: review of the literature. Cancer Invest 2008; 26:104-8.
22. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004; 204:1-10.
23. Tas F, Duranyildiz D, Soydinc HO, Cicin I, Selam M, Uygun K, et al. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2008; 61:721-5.
24. Sudhakar A, Boosani CS. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression. Pharm Res 2008; 25:2731-9.
25. Huang G, Chen L. Tumor vasculature and microenvironment normalization: a possible mechanism of antiangiogenesis therapy. Cancer Biother Radiopharm 2008; 23:661-7.
26. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
27. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA Drug Approval Summary: Bevacizumab (Avastin) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell Lung Cancer. The Oncologist 2007; 12:713-8.
28. Werther K, Christensen IJ, Nielsen H. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62:343-50.
29. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999; 5:487-91. (Pubitemid 29131955)
30. Dietrich J. Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy. The Oncologist 2008; 13:1285-95.
31. Warner-Schmidt JL, Duman RS. VEGF as a potential target for therapeutic intervention in depression. Current Opinion in Pharmacology 2008; 8:14-9.
32. Scagliotti G. Optimizing chemotherapy for patients with advanced non-small cell lung cancer. J Thorac Oncol 2007; 2:86-91. (Pubitemid 46988098)
33. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005; 23:8950-8.